Clinical Trials

US FDA Approves Telix’s Pixclara as First FET-PET Imaging Drug for Brain Cancer

Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians ...

 September 15, 2026 | News

Kelun-Biotech’s Trastuzumab Botidotin Cuts Progression Risk by 61% in Phase III Breast Cancer Study

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational...

 September 15, 2026 | News

Accro Bioscience’s AC-101 Enters China’s Rare Disease Innovative Drug Pilot Programme for Blau Syndrome

Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring...

 September 15, 2026 | News

TenNor’s TNP-2092 Shows 100% Treatment Success in Early, Acute PJI Phase IIa Trial

TenNor Therapeutics, a near-commercial-stage biotechnology company, announced positive topline results from a Phase IIa proof-of-concept (POC) trial of rif...

 September 14, 2026 | News

Exegenesis Bio, Modalis Partner to Advance CRISPR-Based DMD Therapy MDL-201

Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis")  announced that they have signed a research collaboration and license agr...

 September 14, 2026 | News

Gan&Lee Doses First Participant in Phase I Trial of Once-Weekly Oral GLP-1 Candidate GZC8072

Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH...

 September 11, 2026 | News

Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity

- This trial marks the fourth Phase I peptide study for Ascletis this year. - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at ste...

 September 10, 2026 | News

Alebund Secures US FDA IND Clearance for First-in-Class IgA Nephropathy Therapy AP308

Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, announced that it has recen...

 September 10, 2026 | News

Harbour BioMed’s HBM9378 Shows Sustained Asthma Control with Twice-Yearly Dosing Potential

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. ...

 September 10, 2026 | News

Accro, Fosun Pharma Secure China Nod for Phase II/III Trial of AC-201 in Vitiligo

Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Indust...

 September 10, 2026 | News

CelluPro Becomes First Chinese Cell Culture Media Supplier to Secure EXCiPACT GMP Certification

CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certif...

 September 09, 2026 | News

HORIEN Secures Thai FDA Class 4 Approvals for Three Regenerative Medical Devices

Market-entry initiative targets qualified Thai distributors across dental, surgical, wound-care, and regenerative medicine channels, while solidifying glob...

 September 09, 2026 | News

Clover Biopharmaceuticals Reports Positive Phase II Results for RSV-hMPV-PIV3 Combination Vaccines

-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differe...

 September 08, 2026 | News

Rznomics Advances High-Efficiency Circular RNA Production with Engineered STS Technology

Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in t...

 September 08, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close